Does Highmark Cover Prolia?

What Is Prolia and Why Does Coverage Complexity Matter?

Prolia is a RANK-ligand inhibitor that reduces osteoclast-mediated bone resorption. The FDA first approved it on June 1, 2010, for postmenopausal women with osteoporosis at high fracture risk, and later expanded the label to include bone loss associated with androgen-deprivation therapy (ADT) in men with nonmetastatic prostate cancer, aromatase-inhibitor therapy in women with breast cancer, and glucocorticoid-induced osteoporosis in adults [1].

Because Prolia is administered in a physician's office every six months, it usually bills under the medical benefit rather than the pharmacy benefit. That distinction matters enormously for Highmark members: copay amounts, prior-authorization pathways, and appeals processes differ depending on which benefit the claim routes through.

The FREEDOM trial (N=7,868) showed Prolia reduced new vertebral fracture risk by 68% over 36 months compared with placebo (7.2% placebo vs. 2.3% denosumab, P<0.001) [2]. That efficacy data forms the clinical backbone of most insurer coverage criteria, including Highmark's.

How Highmark Structures Prolia Coverage

Highmark Blue Cross Blue Shield operates several distinct product lines: commercial PPO and HMO plans sold through employers, individual marketplace plans, and Medicare Advantage plans (branded as Community Blue, Security Blue, and others). Each product line has its own drug and medical formulary, so coverage details for Prolia can differ substantially within the same insurer umbrella.

Commercial plans. On most Highmark commercial formularies, Prolia sits on a specialty tier, typically Tier 4 or Tier 5. Specialty-tier cost-sharing for injectable drugs under the medical benefit commonly means a percentage coinsurance (often 20-30%) after the deductible is met, rather than a flat copay. A single Prolia dose has a list price of approximately $1,400-$1,600 as of 2024, so even 20% coinsurance can mean $280-$320 per dose out-of-pocket before any manufacturer coupon is applied [3].

Medicare Advantage plans. Security Blue and other Highmark Medicare Advantage products follow CMS formulary guidelines. Medicare Part B covers Prolia when administered in a physician's office, and Part B coinsurance is typically 20% after the Part B deductible ($240 in 2024). Medicare Advantage plans may reduce that to a fixed copay, often $0-$80 per injection depending on the plan's supplemental benefit design.

Marketplace plans. ACA marketplace plans offered by Highmark must cover osteoporosis screening under the preventive-services mandate, but Prolia treatment is not a preventive service. It falls under standard specialty drug cost-sharing rules.

The framework below describes the three-gate coverage pathway that applies to the majority of Highmark plan types:

1. Medical necessity gate. The prescribing provider must document an FDA-approved indication (postmenopausal osteoporosis, ADT-related bone loss, aromatase-inhibitor-related bone loss, or glucocorticoid-induced osteoporosis).
2. DEXA gate. Most plans require a dual-energy X-ray absorptiometry (DEXA) scan result showing a T-score at or below -2.5, or a T-score at or below -1.0 combined with a documented prior fracture or high FRAX score.
3. Step-therapy gate. The majority of Highmark commercial plans require a documented trial of an oral bisphosphonate (alendronate or risedronate) for at least six months, with documented failure, intolerance, or a clinical contraindication before Prolia is approved.

Prior Authorization Requirements in Detail

Nearly every Highmark plan type requires prior authorization (PA) for Prolia. Failure to obtain PA before administering the injection is the single most common reason claims are denied.

The PA submission typically requires the following clinical documentation:

• ICD-10 diagnosis code (M81.0 for postmenopausal osteoporosis is most common)
• Most recent DEXA T-score report with scan date
• FRAX 10-year fracture probability if T-score is between -1.0 and -2.5
• Documentation of bisphosphonate trial: drug name, dose, duration, and reason for discontinuation or contraindication
• Prescriber's NPI and the facility where the drug will be administered

Highmark typically processes standard PA requests within 14 calendar days and urgent requests within 72 hours, consistent with CMS regulations and Pennsylvania insurance law.

The American Association of Clinical Endocrinologists (AACE) 2020 Clinical Practice Guidelines for osteoporosis state: "Denosumab is an appropriate first-line agent for patients with severe osteoporosis (T-score <-2.5 with fracture) or for patients who cannot tolerate or are at high risk for bisphosphonate-related complications" [4]. Citing this guideline language in a PA submission can strengthen the case for bypassing step therapy when a clinical contraindication to bisphosphonates exists (for example, stage 3b-5 chronic kidney disease, documented esophageal stricture, or prior atypical femoral fracture on bisphosphonate therapy).

Step Therapy: What Counts as a Sufficient Trial?

Highmark's step-therapy criteria for Prolia generally accept the following as a completed bisphosphonate trial:

• Alendronate 70 mg weekly for at least 6 continuous months with documented gastrointestinal intolerance (Grade 2 or higher adverse event per clinical notes)
• Risedronate 35 mg weekly for at least 6 continuous months with similar intolerance documentation
• Any bisphosphonate trial in a patient with a DEXA-confirmed new fracture during therapy, indicating treatment failure
• Physician attestation of a clinical contraindication (creatinine clearance <35 mL/min, active esophageal disease, inability to sit upright for 30 minutes)

Zoledronic acid (Reclast), an IV bisphosphonate, does not always satisfy step therapy because some Highmark plans treat IV bisphosphonates and Prolia as parallel specialty agents rather than as a sequential step. Confirm this with Highmark's PA team before assuming an IV zoledronic acid trial satisfies the oral bisphosphonate requirement.

The HORIZON Key Fracture Trial (N=7,765) found that annual zoledronic acid infusion reduced hip fracture risk by 41% and vertebral fracture risk by 70% over 36 months [5]. That head-to-head context matters clinically when arguing to a plan that a patient has already tried the most potent available bisphosphonate and still meets criteria for Prolia.

How to Submit a Prior Authorization and What to Expect

Prescribers typically submit Prolia PAs through one of three pathways with Highmark:

1. NaviMedix / AIM Specialty Health portal (used by many Highmark commercial plans for specialty drug PAs)
2. Availity web portal (standard for most Highmark medical-benefit requests)
3. Fax submission to Highmark's pharmacy or medical management department

Once submitted, approval generates a PA reference number that must appear on the claim. PA approvals for Prolia are typically valid for 12 months, covering one injection per approval period. Because Prolia is given every six months, a rolling PA renewal cycle is needed.

If the initial PA is denied, the provider receives an Explanation of Benefits (EOB) citing the specific denial reason, typically one of three: insufficient step therapy, missing DEXA documentation, or non-covered indication. That denial letter triggers appeal rights.

Appeals: What to Do After a Prolia Denial

A Highmark denial is not the end of the road. Federal law (under the ACA and ERISA for self-funded plans) guarantees at least two internal appeal levels and an external independent review. The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) notes that physician-submitted appeals with full clinical documentation succeed at higher rates than administrative appeals without supporting records [6].

Practical steps to maximize appeal success:

Step 1: Gather the clinical record completely. Include the denial letter, DEXA report, FRAX calculation printout, bisphosphonate trial records, and any relevant lab results (serum creatinine, bone turnover markers such as serum CTX or P1NP).

Step 2: Write a letter of medical necessity. The physician should explain specifically why Prolia is the medically appropriate choice for this individual patient, referencing AACE guidelines and the FREEDOM trial fracture-reduction data [2].

Step 3: Request a peer-to-peer review. Highmark allows prescribing physicians to speak directly with the plan's reviewing physician before or after a denial. This conversation often resolves disputes faster than a formal written appeal. Call Highmark's Provider Relations line and ask for the peer-to-peer review process for the specific PA denial case number.

Step 4: File the formal appeal within the deadline. Commercial plans typically allow 180 days from the denial date. Medicare Advantage plans allow 60 days. Missing the deadline forfeits appeal rights.

Step 5: Request external review if both internal appeals fail. Pennsylvania Insurance Commission and CMS both oversee independent external review organizations. External reviewers are bound by medical evidence, not insurer formulary preferences, and overturn medically complex denials at a meaningful rate.

Cost-Assistance Options When Coverage Falls Short

Even with Highmark coverage, Prolia's specialty-tier cost-sharing can create barriers. Several assistance pathways exist:

Amgen Assist360. Amgen's patient-support program offers a copay card for commercially insured patients that may reduce the per-dose cost-share to as little as $0, subject to eligibility criteria. Patients with Medicare are not eligible for manufacturer copay cards under federal anti-kickback provisions.

Amgen Safety Net Foundation. For uninsured or underinsured patients, the Safety Net Foundation provides Prolia at no cost to qualifying individuals below certain income thresholds. Eligibility is typically set at household income at or below 500% of the federal poverty level.

State pharmaceutical assistance programs. Pennsylvania's PACE and PACENET programs may cover Prolia costs for Medicare beneficiaries over age 65 who meet income criteria, partially offsetting Part B coinsurance.

Hospital financial assistance / 340B pricing. Patients receiving Prolia at a federally qualified health center or a 340B-eligible hospital outpatient department may have access to substantially lower drug acquisition costs, which can reduce the facility's cost-share pass-through.

The FDA's 2022 approval of Jubbonti (denosumab-bbdz) and Wyost as biosimilars to Prolia and XGEVA, respectively, may eventually reduce list prices and formulary tier placement, but as of mid-2025, biosimilar market penetration for this drug class remains limited [7]. Highmark has not yet published a formal policy preferring a biosimilar over reference Prolia on most formularies, though formulary evolution should be monitored at each plan year's open enrollment.

Clinical Context: Who Is Most Likely to Get Prolia Approved by Highmark?

Not every patient with low bone density will meet Highmark's medical necessity threshold. The patients most likely to receive rapid PA approval share these characteristics:

• Postmenopausal women with a DEXA T-score at or below -2.5 at the lumbar spine or femoral neck
• Men on ADT for prostate cancer with documented bone density decline (T-score <-1.0 at femoral neck after at least 6 months of ADT)
• Women on aromatase inhibitors for breast cancer with T-score <-2.0 or documented fragility fracture
• Any patient with a documented prior fragility fracture plus T-score <-1.0 (the "very high risk" category per AACE 2020 [4])
• Patients with renal impairment (creatinine clearance <35 mL/min) who have a clinical contraindication to bisphosphonates, since denosumab requires no dose adjustment in renal impairment [8]

Patients who are likely to face more difficulty include those with T-scores between -1.0 and -2.5 without a prior fracture, those who have not attempted any bisphosphonate, and those with diagnoses not on Prolia's FDA label (for example, premenopausal women without a specific high-risk indication).

What Highmark Providers Should Document at Every Osteoporosis Visit

Thorough chart documentation before submitting a PA reduces denial rates and shortens approval timelines. At each visit, providers should record:

• DEXA T-scores at lumbar spine (L1-L4), femoral neck, and total hip with the date of the scan and comparison to prior scans
• FRAX 10-year probability with and without bone density (using the WHO FRAX tool for the United States)
• Any incident fractures since the last visit, including vertebral fractures identified incidentally on imaging
• Adverse effects of any prior osteoporosis therapy, documented with symptom grade and dates
• Relevant lab values: 25-hydroxyvitamin D, serum calcium, creatinine, and bone turnover markers if obtained
• Current calcium and vitamin D supplementation with doses (at least 1,000-1 to 200 mg elemental calcium daily and 600-800 IU vitamin D per National Osteoporosis Foundation guidance [6])

This documentation creates a contemporaneous clinical record that mirrors Highmark's PA review criteria, making it straightforward for the utilization management team to approve the request on first submission.

Monitoring and Renewal Considerations After Approval

Prolia requires adherence every six months without lapses. Discontinuation without transitioning to an antiresorptive agent (typically a bisphosphonate) carries a real risk of rebound bone loss and multiple vertebral fractures. A 2017 cohort analysis published in the Journal of Bone and Mineral Research (N=1,001 patients who discontinued denosumab) found that vertebral fracture incidence increased sharply in the 12 months after discontinuation in patients who did not receive follow-on bisphosphonate therapy [9].

Highmark's PA renewal requirements typically mirror initial approval requirements: updated DEXA (at least every 24 months), continued documentation of the original indication, and absence of new contraindications. Providers should initiate renewal PA at least 60 days before the scheduled injection date to avoid a gap in therapy that could trigger rebound fracture risk.